3-(Dimethylamino)-2-(3-nitrophenyl)prop-2-enenitrile

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(Dimethylamino)-2-(3-nitrophenyl)prop-2-enenitrile
• 英文别名: 3-(dimethylamino)-2-(3-nitrophenyl)prop-2-enenitrile
• 化学式: C₁₁H₁₁N₃O₂
• 分子量: 217.227
• InChiKey: XPYKZWWSLXMTNC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  72.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-氨基吡唑 、 3-(Dimethylamino)-2-(3-nitrophenyl)prop-2-enenitrile 在 盐酸 作用下， 以 乙醇 、 水 为溶剂， 反应 16.0h， 生成 6-(3-nitro-phenyl)-pyrazolo[1,5-α]pyrimdin-7-ylamine
  参考文献：
  名称：

  7-Aminopyrazolo[1,5-a]pyrimidines as Potent Multitargeted Receptor Tyrosine Kinase Inhibitors

  摘要：

  7-Aminopyrazolo[1,5-a]pyrimidine urea receptor tyrosine kinase inhibitors have been discovered. Investigation of structure-activity relationships of the pyrazolo[1,5-a]pyrimidine nucleus led to a series of 6-(4-N,N'-diphenyl)ureas that potently inhibited a panel of vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) kinases. Several of these compounds, such as 34a, are potent inhibitors of kinase insert domain-containing receptor tyrosine kinase (KDR) both enzymatically (< 10 nM) and cellularly (< 10 nM). In addition, compound 34a possesses a favorable pharmacokinetic profile and demonstrates efficacy in the estradiol-induced murine uterine edema (UE) model (ED(50) = 1.4 mg/kg).

  DOI：

  10.1021/jm701397k
• 作为产物：
  描述：

  3-硝基苯乙腈 、 N,N-二甲基甲酰胺二甲基缩醛 以 甲苯 为溶剂， 反应 16.0h， 生成 3-(Dimethylamino)-2-(3-nitrophenyl)prop-2-enenitrile
  参考文献：
  名称：

  7-Aminopyrazolo[1,5-a]pyrimidines as Potent Multitargeted Receptor Tyrosine Kinase Inhibitors

  摘要：

  7-Aminopyrazolo[1,5-a]pyrimidine urea receptor tyrosine kinase inhibitors have been discovered. Investigation of structure-activity relationships of the pyrazolo[1,5-a]pyrimidine nucleus led to a series of 6-(4-N,N'-diphenyl)ureas that potently inhibited a panel of vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) kinases. Several of these compounds, such as 34a, are potent inhibitors of kinase insert domain-containing receptor tyrosine kinase (KDR) both enzymatically (< 10 nM) and cellularly (< 10 nM). In addition, compound 34a possesses a favorable pharmacokinetic profile and demonstrates efficacy in the estradiol-induced murine uterine edema (UE) model (ED(50) = 1.4 mg/kg).

  DOI：

  10.1021/jm701397k

文献信息

• Organic compounds
  申请人：Bold Guido

  公开号：US20050222171A1

  公开（公告）日：2005-10-06

  The invention relates to the use of pyrazolo[1,5a]pyrimidin-7-yl amine compounds and salts thereof in the treatment of kinase dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases, novel pyrazolo[1,5a]pyrimidin-7-yl amine compounds, and a process for the preparation of the novel pyrazolo[1,5a]pyrimidin-7-yl amine compounds.

  该发明涉及在激酶依赖性疾病的治疗中使用吡唑并[1,5a]嘧啶-7-基胺化合物及其盐，并用于制备用于治疗该类疾病的药物制剂，新型吡唑并[1,5a]嘧啶-7-基胺化合物，以及制备新型吡唑并[1,5a]嘧啶-7-基胺化合物的方法。
• Use of Pyrazolo(1,5A)Pyrimidin-7-YL Amine Derivatives in the Treatment of Neurological Disorders
  申请人：Sivasankaran Rajeev

  公开号：US20090069315A1

  公开（公告）日：2009-03-12

  The invention relates to methods of using the compounds of the invention, including pyrazolo[1,5a]pyrimidin-7-yl amine compounds and salts thereof, as well as pharmaceutical compositions comprising the same, in the treatment of Eph receptor-related (e.g., neurological) injuries and disorders. The invention also relates to modulating the activity of an Eph receptor in a cell, stimulating neural regeneration, and reversing neuronal degeneration, by administering a compound of the invention to a cell or subject in an effective amount.

  该发明涉及使用该发明的化合物的方法，包括吡唑并[1,5a]嘧啶-7-基胺化合物及其盐，以及包含相同的药物组合物，在治疗Eph受体相关（例如神经）损伤和疾病方面的用途。该发明还涉及通过向细胞或受体中有效量的给予该发明的化合物，来调节Eph受体的活性，刺激神经再生，并逆转神经细胞的退化。
• [EN] PYRAZOLO[1,5-A]PYRIMIDIN-7-YL-AMINE DERIVATIVES FOR USE IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES<br/>[FR] DERIVES DE PYRAZOLO[1,5-A]PYRIMIDIN-7-YL-AMINE DESTINES A ETRE UTILISES DANS LE TRAITEMENT DE MALADIES DEPENDANTES DE LA PROTEINE KINASE
  申请人：NOVARTIS AG

  公开号：WO2005070431A1

  公开（公告）日：2005-08-04

  The invention relates to the use of pyrazolo[1,5a]pyrimidin-7-yl amine compounds and salts thereof in the treatment of kinase dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases, novel pyrazolo[1,5a]pyrimidin-7-yl amine compounds, and a process for the preparation of the novel pyrazolo[1,5a]pyrimidin-7-yl amine compounds.

  该发明涉及使用吡唑并[1,5a]嘧啶-7-基胺化合物及其盐来治疗激酶依赖性疾病，并用于制备用于治疗该疾病的制药制剂，新的吡唑并[1,5a]嘧啶-7-基胺化合物，以及制备新的吡唑并[1,5a]嘧啶-7-基胺化合物的方法。
• PYRAZOLO[1,5-A]PYRIMIDIN-7-YL-AMINE DERIVATIVES FOR USE IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES
  申请人：Novartis AG

  公开号：EP1708710A1

  公开（公告）日：2006-10-11
• USE OF PYRAZOLO[1,5A]PYRIMIDIN-7-YL AMINE DERIVATIVES IN THE TREATMENT OF NEUROLOGICAL DISORDERS
  申请人：NOVARTIS AG

  公开号：EP1993552A2

  公开（公告）日：2008-11-26